Half of advanced melanoma patients live for 10 years with double drug treatment - The Guardian
- Half of advanced melanoma patients live for 10 years with double drug treatment The Guardian
- New skin cancer treatment helps patients live 10 years after diagnosis, study finds The Telegraph
- Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms Yahoo Finance
- Neoadjuvant Immunotherapy Superior to Targeted Therapy in Stage III Melanoma AJMC.com Managed Markets Network
- UChicago, one of the first to try new cancer therapy, treats woman's life-threatening melanoma Crain's Chicago Business